NHS-only South East London clinical guidance on managing vitamin D insufficiency and deficiency in adults, excluding people with chronic kidney disease stage 4 and above. Covers risk factors, indications for testing, treatment and maintenance supplementation, specific patient groups, sunlight and dietary advice, monitoring, toxicity, drug interactions, and product options. Originally approved in July 2017, last reviewed and updated in February 2025, with review scheduled for February 2027 or sooner if indicated. The document supports rather than replaces individual clinical judgement and prohibits commercial or marketing use.
Free preview text
The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
SEL Clinical Guideline for the Management of Vitamin D insufficiency and deficiency in Adults
Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.
Original Approval date: July 2017 Last reviewed and updated: February 2025 Review date: February 2027 (or sooner if indicated)
South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London
Integrated Care System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and
GSTFT/KCH /SLaM/ Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust
Page | 1
This guideline does not cover the management of vitamin d insufficiency and deficiency in people with stage 4 and above chronic kidney disease
This guideline does not cover the management of vitamin d insufficiency and deficiency in people with chronic
kidney disease (CKD) stage 4 and above. This document is for guidance only and not intended to replace the health
professional’s clinical judgement for individual patients. The South East London Integrated Medicines Optimisation Committee
has separate guidance for management of Vitamin D deficiency and insufficiency in children.
1. Introduction
Vitamin D is essential for musculoskeletal health as it promotes calcium absorption from the bowel:
enables mineralisation of newly formed osteoid tissue in bone and plays an important role in muscle
function [1]. The term 'vitamin D' generally refers to two very similar molecules. Vitamin D3, also known
as colecalciferol, is the most abundant in humans and is produced in the skin following exposure to
sunlight [1]. Vitamin D2, or ergocalciferol, occurs naturally in some mushrooms and yeast. The amount in
most vegetables is negligible.
The body converts both forms of vitamin D to 25-hydroxyvitamin D (25(OH)D). Tests to assess vitamin D
status measure levels of 25(OH)D in the blood. 25(OH)D is itself converted in the kidney to the biologically
active form 1,25-dihydroxyvitamin D, also known as calcitriol.
The main manifestation of vitamin D deficiency is osteomalacia in adults, which is generally associated
with a serum 25(OH)D concentration of less than 25nmol/L [2]. There is a growing understanding of the
importance of vitamin D in terms of its potential role in the prevention of non-skeletal disorders such as
auto-immune disease, cancer, mental health problems and cardiovascular disease.
2. Purpose and Scope
This document is a South East London-wide guideline broadly based on the Royal Osteoporosis -
Better bone health for everybody [1] and the Clinical Knowledge Summaries (CKS) [2].
Before using this guidance refer to a specialist for advice if the patient has:
1. A diagnosis of stage 4 and above CKD
2. A history of renal stones or sarcoidosis
3. Hypercalcaemia / hyperparathyroidism
Vitamin D supplementation during winter: PHE and NICE statement 2020[4]
Public Health England and NICE [3] recommends that ALL people should consider buying a daily
supplement over the counter (OTC) containing 10micrograms (mcg)/400 International Units (IU) of
vitamin D in autumn and winter (October to early March). At risk groups should take daily supplements
all year round.
Adults who are at higher risk of vitamin D deficiency include people [2]:
• Aged 65 years and over.
• Who have low or no exposure to the sun, for example those who cover their skin for cultural,
religious, or health reasons; who are housebound; or who are confined indoors for long periods.
• Who have darker skin pigmentation, for example people of African, African-Caribbean, or South
Asian origin, etc.
• With a gastrointestinal or malabsorption disorder, or following weight loss surgery, resulting in a
reduced ability to absorb fat-soluble vitamin D.
• With severe liver disease or end-stage chronic kidney disease (CKD).
• Taking certain drugs that increase the risk of vitamin D deficiency (see Section 9 for details)
• Are pregnant or breastfeeding, due to the risk of foetal neonatal hypovitaminosis.
• Are obese (body mass index greater than 30 kg/m2) – vitamin D may be sequestered into adipose
tissue reducing bioavailability.
South East London Clinical Guideline for the Management of Vitamin D
Insufficiency and Deficiency in ADULTS – Excluding CKD stage 4 and above
Page 2
SEL Clinical Guideline for the Management of Vitamin D insufficiency and deficiency in Adults
Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.
Original Approval date: July 2017 Last reviewed and updated: February 2025 Review date: February 2027 (or sooner if indicated)
South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care System: NHS South East London (covering the boroughs of
Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS Foundation Trusts and Lewisham & Greenwich NHS Trust
Page | 2
3. Treatment of Vitamin D Deficiency
Flow Chart 1: Management of Vitamin D levels in adults over 18 years of age (Excluding CKD 4 and above)
Routine testing for 25 hydroxyvitamin D level is not recommended
* Unlicensed dose – Agreed by GSTT and KCH **** NHS Choices information on Vitamin D: Vitamin D – NHS (www.nhs.uk)
** Unlicensed food supplement product *****Resources:, Calcium calculator: CGEM Calcium Calculator (ed.ac.uk)
***otc-guidance-for-ccgs.pdf (england.nhs.uk)
Patient with high risk factors of vitamin D deficiency
Does the patient have SYMPTOMS indicative of rickets, osteomalacia or hypocalcaemia?
Clinical features of vitamin D deficiency include musculoskeletal symptom such as:
• Muscle pain
• Proximal muscle weakness
• Rib, hip, pelvis, thigh and foot pain are typical.
• Fractures
Raised alkaline Phosphatase (ALP) – can be found in liver function blood test
- may indicate more severe osteomalacia.
Routine replacement / maintenance therapy self-care only
• Give lifestyle advice NHS patient information on Vitamin D: Vitamin D - NHS
(www.nhs.uk)
• Recommend OTC oral colecalciferol 800-2000 units daily suitable year-round
to be initiated one month after loading dose completed, for example.
Valupak D3 1,000 units tablets (Cost price: £0.59/60 tablets)
Patient to purchase OTC for approx. <£2.00 (2 months supply)
prescribe Stexerol-D3® 1,000 unit tablets ONLY for patients with conditions
exempt from NHSE self-care directive (NHS SEL ICB self- care leaflet )
• Assess the person's need for calcium supplementation. To assess the
person's dietary calcium intake. Consider using an online calcium calculator,
such as the UK Centre for Calcium Genomic and Experimental Medicine
(CGEM) calculator: CGEM Calcium Calculator (ed.ac.uk).
TEST for vitamin D levels and bone profile
Moderate to severe symptomatic hypocalcaemia is a medical emergency and
will need acute admission and treatment. Refer to specialist if CKD 4.
Public Health England and NICE 2020
From October to March, EVERYONE should consider taking a daily supplement
containing 10 micrograms (400 units) of vitamin D for prevention, to help keep
bones, teeth and muscles healthy. This can be purchased over the counter (OTC).
Deficient
<25nmol/L (<10mcg/L)
Insufficient
25-50nmol/L (10-20 mcg/L)
Sufficient
>50nmol/L (>20 mcg/L)
Monitoring: check serum calcium levels 4 weeks
after loading dose, in case primary hyperPTH is
unmasked, check vitamin D level at 12 weeks to
allow level to plateau
/ (
Check adherence, consider
specialist advice/referral.
NO
YES
NO
YES
NO
Loading dose: Prescribe as ACUTE items. (No licensed product for Vegan, see section 5.3 for details):
BNF Product Choice Recommended Dosage Halal/Kosher Vegetarian
1st Line Invita® D3 50,000 unit capsules One cap weekly for 6 weeks Y N
Alternative Stexerol® D3 25,000units tablets Two caps weekly for 6 weeks Y Y
Pregnant &
Breastfeeding women
Thorens® 10,000iu/ml oral
solution
0.4mls (20 drops – 4000iu) daily for 10 weeks
(Unlicensed dose agreed by GSTT/KCH) Y Y
(Total of approximately 300,000 units colecalciferol per treatment course)
Primary Care: Prescribe by brand to ensure a licensed product or preparation suitable for specific patients (e.g. vegetarians) is dispensed (refer to
Appendix I for all licensed preparations).
Secondary care only : off-label rapid daily dosing might be considered e.g. Colecalciferol 20,000iu bd for 7 days
If patient cannot tolerate oral preparation/severe gastrointestinal malabsorption
IM injection: 1 injection of 300,000 units ergocalciferol (for specialist initiation only)
Page 3
SEL Clinical Guideline for the Management of Vitamin D insufficiency and deficiency in Adults
Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.
Original Approval date: July 2017 Last reviewed and updated: February 2025 Review date: February 2027 (or sooner if indicated)
South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care
System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS
Foundation Trusts and Lewisham & Greenwich NHS Trust
Page | 3
4. When to test for Vitamin D deficiency
NICE [3] recommends that health professionals should NOT routinely test vitamin D in people unless:
• they have symptoms of vitamin D deficiency e.g. chronic widespread pain with other features of
osteomalacia (such as proximal muscle weakness)
• there is a clinical need e.g. suspected bone disease such as osteomalacia/osteoporosis, known
bone disease, where correction of vitamin D deficiency is needed prior to specific treatment [2].
e.g. starting patients on a potent antiresorptive agent (zoledronate or denosumab or
teriparatide)
5. Consideration for specific cohort of patients
5.1 Pregnant and Breastfeeding Mothers
Adequate vitamin D intake may be difficult to achieve with diet alone, and pregnant women are advised to
buy over the counter vitamin supplements or signposted to Healthy Start scheme or any similar scheme.
Healthy Start Women’s vitamin tablets are supplied free of charge to pregnant and breastfeeding women who
are eligible beneficiaries under the Healthy Start government led scheme. [4] Healthy Start Women’s vitamin
tablets contain 70 milligrams of vitamin C, 10 micrograms (400 units) of vitamin D and 400 micrograms of
folic acid. For more information, please visit www.healthystart.nhs.uk
• Prescribing for vitamin D deficient pregnant women [5}
There is currently no UK guidance on managing vitamin D deficiency in pregnancy. International
guidance recommends a daily intake of 1,000-2,000units, with upper limits of 4,000units daily advised
in the American College of Obstetricians and Gynaecologists (ACOG) guidelines. A new born baby's
vitamin D status is largely determined by the mother's level of vitamin D during pregnancy.[3]
The decision to treat vitamin D deficiency should be based on local laboratory findings and be guided
by local vitamin D reference ranges.
The ACOG make no recommendations in their guidance around monitoring of serum calcium or
vitamin D levels following treatment with vitamin D in pregnancy. In certain situations, higher doses
may be used or recommended by specialists.
• Managing vitamin D deficiency in breast feeding women
Higher doses of vitamin D for treating deficiency may be considered in a pregnant woman if local
laboratory results indicate a need for treatment.
For further information on the use of vitamin D during pregnancy, please visit bumps - best use of medicine
in pregnancy, Vitamins, minerals and supplements in pregnancy NHS (www.nhs.uk), Healthy eating and
vitamin supplements in pregnancy patient information (rcog.org.uk)
5.2 Care homes
Care home providers are required to meet resident’s full nutritional needs to sustain life and good health, and
reduce the risks of malnutrition, in line with regulation 14 (Part A) of the Health and Social Care Act 2008
(Regulated Activities) Regulations 2014[6] and advice from the Care Quality Commission (CQC). In addition
to provision of nutritious meals, this should include food supplements where necessary, such as vitamin D.
Vitamin D deficiency in care home residents should be managed the same way as according to flowchart 1.
5.3 People with diet or cultural requirements
Information on choosing an oral vitamin D preparation for vegetarians or vegans and choosing a suitable
product for patients with a soya or peanut allergy is available.
Page 4
SEL Clinical Guideline for the Management of Vitamin D insufficiency and deficiency in Adults
Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.
Original Approval date: July 2017 Last reviewed and updated: February 2025 Review date: February 2027 (or sooner if indicated)
South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care
System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS
Foundation Trusts and Lewisham & Greenwich NHS Trust
Page | 4
6. Natural ways of increasing Vitamin D levels
6.1 Safe Sun exposure
Sun exposure is the main source of vitamin D and this should be balanced with the risks of excessive
exposure. Sunburn should always be avoided. Little and often sun exposure is best for vitamin D synthesis.
On 21st July 2016, Public Health England issued new guidance on vitamin D based on the
recommendations of the Scientific Advisory Committee on Nutrition. The advice notes that vitamin D is
made in the skin on exposure to UVB in sunlight and that in spring and summer, the majority of the
population get sufficient vitamin D through sunlight on the skin and a healthy, balanced diet. However,
since it is difficult to quantify, a daily dietary intake of 10 micrograms equivalent to 400 international units
(IU) is recommended for everyone particularly in the autumn and winter months.
Individuals from ethnic minority groups with dark skin, e.g. from African, Afro-Caribbean and South Asian
backgrounds etc, may not get enough vitamin D from sunlight in the summer and therefore should consider
taking a supplement all year round.
Following Public Health England advice, prescribing of vitamin D purely for supplementation should be
avoided and patients/parents/carers should be requested to purchase vitamin D over the counter.
Unprotected sun exposure should be avoided in patients with the following conditions: sensitive skins, skin
cancer, porphyrias, xeroderma pigmentosum, albinism, granulomatous disease (sarcoid but not
tuberculosis) and lymphoma.
Unprotected sun exposure should also be avoided in patients who are taking the following medications:
sulphonamides, phenothiazines, tetracyclines, quinolones, psoralens, isotretinoin or any other
photosensitising medications.
6.2 Dietary advice
Please refer to the NHS choices website on vitamin D for sources of dietary vitamin D (Vitamin D - NHS
(www.nhs.uk)).
7. Requirements for monitoring vitamin D levels[3]
Status Monitoring Advice
High risk patients
(no symptoms)
Routine monitoring of plasma 25(OH)D is generally unnecessary.
Advice to buy Vitamin D supplement (800 – 2000iu) daily OTC.
Symptomatic patients
Monitoring may be appropriate in patients with symptomatic
vitamin D deficiency or malabsorption and where poor compliance
with medication is suspected.
Symptoms indicative of rickets, osteomalacia or hypocalcaemia
• Muscle pain
• Proximal muscle weakness
• Rib, hip, pelvis, thigh and foot pain are typical.
• Fractures
Raised alkaline Phosphatase (ALP) may indicate more severe
osteomalacia
Post treatment dose
Check adjusted calcium within 1 month after the administration of
the last loading dose to detect those with primary
hyperparathyroidism. If hypercalcaemia is detected stop further
vitamin D supplementation and investigate
Note: specialists may recommend specific vitamin D treatments outside of this guideline for specific patient
cohorts e.g. patients with CKD stage 4 and above therefore GPs may be requested to carry out specific
monitoring.
Page 5
SEL Clinical Guideline for the Management of Vitamin D insufficiency and deficiency in Adults
Not to be used for commercial or marketing purposes. Strictly for use within the NHS only.
Original Approval date: July 2017 Last reviewed and updated: February 2025 Review date: February 2027 (or sooner if indicated)
South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care
System: NHS South East London (covering the boroughs of Bexley/Bromley/Greenwich/ Lambeth/Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS
Foundation Trusts and Lewisham & Greenwich NHS Trust
Page | 5
Routine monitoring of 25(OH)D is clinically unnecessary, but may be appropriate if:
a) symptoms of vitamin D deficiency continue.
b) malabsorption is suspected (may need advice from or referral to a specialist)
c) poor compliance with medication is suspected
It takes at least 3-6 months to achieve steady state levels of 25(OH)D therefore do not routinely check
levels before this. If there is no improvement clinically or in 25(OH)D status and the patient is compliant
with the loading regimen, refer to a specialist [2]
8. Vitamin D toxicity
Vitamin D toxicity is rare. The Food and Nutrition Board of the Institute of Medicine [7} has summarised the
evidence from a few studies of vitamin D [5], which covered a range of doses (800 to 300,000 units/day)
and duration (months to years). It concluded that vitamin D below 10,000 units/day is not usually associated
with toxicity, whereas doses equal to or above 50,000 units/day for several weeks or months are frequently
associated with toxicity, including documented hypercalcaemia.
Excessive intake of vitamin D can lead to hypercalcaemia and its associated effects including apathy,
anorexia, constipation, diarrhoea, dry mouth, headache, nausea, vomiting, thirst, and weakness. Later
symptoms are often associated with calcification of soft tissues and include bone pain, cardiac arrhythmias,
hypertension, renal damage, psychosis (rare) and weight loss.
Patients with blood levels more than 374 nmol/L are clinically considered to have Vitamin D toxicity. If
toxicity is suspected, vitamin D must be withdrawn, hydration should be assessed (serum calcium and renal
function are to be checked urgently), since emergency inpatient care with rehydration is usually indicated.
If the person is taking calcium supplements, advise them to stop.
Dosage should be individualised for each patient based on indication, patent specific parameters and
response (Clinicians are to pay attention to check whether a recent loading dose has been prescribed
before prescribing loading dose). There is a wide range of doses used for different clinical indications and
a number of different treatment regimens recommended in literature. Treatment regimens include both
daily, weekly and monthly administration frequencies. However, most licensed products stated that the
dose should not exceed 4,000 units/day or equivalent weekly [40,000 units/week] or monthly dose therefore
more than 10,000 units/day is off-label use and should not be recommended to continue in primary care
unless a robust monitoring mechanism is available.
For further information, please refer to Safety considerations when using Vitamin D – SPS - Specialist
Pharmacy Service – The first stop for professional medicines advice.
9. Potential drug interactions associated with vitamin D [2]
Clinicians are to adjust dosage and recheck serum Vitamin D level sooner (2-4 weeks), or seek specialist
advice as appropriate during concurrent treatment with these drugs:
Some antiepileptic drugs
(carbamazepine,
phenytoin, or barbiturates)
These can increase the metabolism of vitamin D, leading to a reduction in
the effects of vitamin D.
Higher doses of vitamin D may be needed
Cardiac glycosides Excessive dosing of vitamin D can induce hypercalcaemia, which may
enhance the effects of digoxin and other cardiac glycosides (leading to an
increased risk of digoxin toxicity and serious arrhythmias).
Close monitoring (and possibly a dose reduction of vitamin D) is needed
during concurrent use.
South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above: summary, contents and background
This guide helps you understand the scope of South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.
Summary and overview
South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above is a 7-page documentcredited to Juno M. Ravenhill. NHS-only South East London clinical guidance on managing vitamin D insufficiency and deficiency in adults, excluding people with chronic kidney disease stage 4 and above. Covers risk factors, indications for testing, treatment and maintenance supplementation, specific patient groups, sunlight and dietary advice, monitoring, toxicity, drug interactions, and product options. Originally approved in July 2017, last reviewed and updated in February 2025, with review scheduled for February 2027 or sooner if indicated. The document supports rather than replaces individual clinical judgement and prohibits commercial or marketing use. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.
The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Vitamin D deficiency, Vitamin D insufficiency, Adult clinical guideline, NHS, South East London, Colecalciferol, Supplementation, Monitoring, Drug interactions, Vitamin D toxicity with the related resources linked below.
Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.
Key topics and reader takeaways
The catalogue connects this document with Vitamin D deficiency, Vitamin D insufficiency, Adult clinical guideline, NHS, South East London, Colecalciferol, Supplementation, Monitoring, Drug interactions, Vitamin D toxicity. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.
A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.
Table of contents and reading guide
The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 7 pages in the player.
Part 1
Vitamin D deficiency
Use this section of the reading guide to identify how Vitamin D deficiency appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 2
Vitamin D insufficiency
Use this section of the reading guide to identify how Vitamin D insufficiency appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 3
Adult clinical guideline
Use this section of the reading guide to identify how Adult clinical guideline appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 4
NHS
Use this section of the reading guide to identify how NHS appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 5
South East London
Use this section of the reading guide to identify how South East London appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 6
Colecalciferol
Use this section of the reading guide to identify how Colecalciferol appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 7
Supplementation
Use this section of the reading guide to identify how Supplementation appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
Part 8
Monitoring
Use this section of the reading guide to identify how Monitoring appears in South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, note important terms, and connect the subject to the wider purpose of the work.
When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.
About Juno M. Ravenhill
Doxxly credits Juno M. Ravenhill as the author or creator of South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.
Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.
About the source organisation
The recorded source for this item is selondonics.org. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.
Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.
Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.
The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.
If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.
Research questions to consider
As you read South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.
A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.
Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.
Frequently asked questions about South East London Clinical Guideline for the Management of Vitamin D Insufficiency and Deficiency in Adults - Excluding CKD Stage 4 and Above
Practical answers about reading, downloading and understanding this document on Doxxly.